Zhuo: study concept and design, acquisition of data, statistical analysis and interpretation, drafting of manuscript. Zhu: acquisition of data, critical revision of manuscript for intellectual content. Jiang: Study design, manuscript revision. Ji: analysis and interpretation of data, critical review of manuscript.
Su: study concept and design, data analysis and interpretation, manuscript review, project supervision, critical revision of manuscript for intellectual content. Xue: analysis and interpretation of data, manuscript revision. Zhou: acquisition of data, interpretation of data, manuscript revision. Correspondence to Chuanjun Zhuo. This work is licensed under a Creative Commons Attribution 4.
Reprints and Permissions. Zhuo, C. Sci Rep 7, Download citation. Received : 06 December Accepted : 03 March Published : 04 April Anyone you share the following link with will be able to read this content:.
Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Aging Clinical and Experimental Research European Journal of Clinical Pharmacology By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
Advanced search. Skip to main content Thank you for visiting nature. Download PDF. Subjects Drug development Parkinson's disease. Table 1 Characteristics of studies included in the network meta-analysis. Full size table. Figure 1: The network plot of included trials. Full size image. In lower half of the table, row treatments are compared against column treatments, whereas in the upper half, column treatments are compared against row treatments.
Figure 2: Clustered ranking plot of the network. Figure 3: Net heat plot. Discussion This study made a comprehensive comparison for the tolerability and efficacy among anti-Parkinson drugs by using a network meta-analysis. Inclusion criteria Studies were included when they met the following criteria: 1 Experiments were designed as RCTs comparing the efficacy of treatments for PD.
Data extraction After reading through the full text, the following information was extracted from each independent study: author, publication year, sample size, gender ratio, design, blind, follow-up, age, condition of PD, intervention and dosage.
Additional Information How to cite this article: Zhuo, C. References 1 Barzilai, A. Google Scholar 3 Hennis, M. Google Scholar 5 Calabrese, V. Google Scholar 6 Hely, M. Google Scholar 7 Connolly, B. Google Scholar 8 Lees, A. Google Scholar 14 Youdim, M. Google Scholar 19 Antonini, A. Google Scholar 21 Barone, P. Google Scholar 22 Barone, P. Google Scholar 24 Bracco, F. Google Scholar 29 Golbe, L. Google Scholar 31 Guttman, M. Google Scholar 33 Hauser, R.
Google Scholar 34 Hauser, R. Google Scholar 35 Hauser, R. Google Scholar 37 Hely, M. Google Scholar 39 Holloway, R. Google Scholar 40 Holloway, R. Google Scholar 44 Inzelberg, R. Google Scholar 46 Jansen, E. Google Scholar 48 Kieburtz, K. Google Scholar 50 Kieburtz, K.
Google Scholar 51 Kim, B. Google Scholar 53 Kulisevsky, J. Google Scholar 61 Mally, J. Google Scholar 65 Mizuno, Y. Google Scholar 66 Mizuno, Y. Google Scholar 69 Myllyla, V. Google Scholar 71 Navan, P. Google Scholar 72 Navan, P. Google Scholar 73 Nicholas, A. Google Scholar 76 Olanow, C. Google Scholar 80 Pahwa, R. Google Scholar 83 Pinter, M. Google Scholar 95 Rektorova, I.
Google Scholar 98 Schapira, A. Google Scholar Sethi, K. Google Scholar Singer, C. Google Scholar Smith, K. Google Scholar Steiger, M. Google Scholar Tetrud, J. Google Scholar Utsumi, H. Google Scholar Weintraub, D. Google Scholar Wermuth, L. View author publications. Ethics declarations Competing interests The authors declare no competing financial interests. Supplementary information. Supplementary Information PDF kb. Rights and permissions This work is licensed under a Creative Commons Attribution 4.
About this article. This means that the MAO enzyme is irreversibly blocked and must be renewed by the formation of new enzyme. Therefore, the effect of selegiline lasts many days after withdrawal. A further review of patients in the DATATOP study concluded that the observed effect was most likely due to the symptomatic effect of selegiline and not any neuroprotective effect.
While selegiline may not have a neuroprotective effect, it undoubtedly delays the need for levodopa therapy. The possibility that levodopa may be toxic to dopaminergic neurones has been intensively debated. If selegiline delays the need for levodopa, then perhaps it will also delay the onset of motor fluctuations.
Early treatment with selegiline, therefore, has not been shown to produce a long-term benefit. They also found that selegiline had no beneficial effect on parkinsonian disability. Purchase access.
Rent article Rent this article from DeepDyve. Access to free article PDF downloads. Save your search. Customize your interests. Create a personal account or sign in to:. Privacy Policy. Article PubMed Google Scholar. BMJ — PLoS Med 6:e Control Clin Trials — Moher D, Pham B, Jones A et al Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet — Jiang DQ, Zhao SH, Li MX et al Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials.
Medicine Baltimore e Article Google Scholar. Stat Med — China Pract Med — Chin J Neuroimmunol Neurol — Guide China Med — China Health Care Nutr — Results from a five-year study.
The Norwegian-Danish Study Group. Eur J Neurol — Ann Neurol — Sun Q Clinical therapeutic effects of selegiline and levodopa polytherapy on the treatment of Parkinsonism dyskinesia. Intern Med — Chin J Pract Nerv Dis — Mod J Neurol Neurosurg —
0コメント